Acquiring Company
WORQ
Acquired Company
Etherna Immunotherapies
MalaysiaManufacturingBiotechnologyTherapeuticsDescription
Valerio Therapeutics has announced the signing of definitive agreements to acquire Etherna Immunotherapies. This acquisition aims to create a leading platform focused on targeted RNA therapies. Additionally, Valerio has secured €40.25 million in PIPE financing from new and existing investors.
Don't miss WORQ's next move
Get an email the moment WORQ makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
M&A Insights
Based on deal dataFrequently asked
Who acquired Etherna Immunotherapies?
Etherna Immunotherapies was acquired by WORQ, based in Malaysia. The deal was reported on August 24, 2026. Malaysia-based co-working space provider with a goal to expand its co-working space operations. WORQ is privately held.
When did WORQ acquire Etherna Immunotherapies?
WORQ's acquisition of Etherna Immunotherapies was reported on August 24, 2026. Valerio Therapeutics has announced the signing of definitive agreements to acquire Etherna Immunotherapies. This acquisition aims to create a leading platform focused on targeted RNA therapies. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Etherna Immunotherapies do?
Etherna Immunotherapies is a leading technology platform company specializing in mRNA and lipid nanoparticle technologies. They have developed advanced manufacturing capabilities up to GMP. It is privately held, operating in Manufacturing.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.